EchoIQ Ltd (ASX:EIQ)'s Philip Woolff speaks with Proactive’s Elisha Newell about the medtech business and its work in heart health solutions. With a focus on aortic stenosis, Woolff describes how Echo IQ differentiates itself from its peers by using and developing artificial intelligence to treat heart disease. The EIQ chief operating officer delves into the exclusive access the company has to the world’s biggest database of echocardiographic data linked to mortality and what this means in terms building algorithms to better view risk and probability of death around aortic stenosis in the first instance. The company works with globally influential leaders in this space as it looks to commercialise the product, by adhering to scientific rigour, discipline, safety and compliance combined with innovation. Finally, Woolff describes the end markets EIQ is targeting, the discussions it is in with major players in the medtech space and the privilege it has to present at the European Society of Cardiology.
Echo IQ continues on its very healthy path to commercialisation
